AGIO.NASDAQAgios Pharmaceuticals, INC

Form 4: Agios Pharmaceuticals Director Jacqualyn Fouse Reports Stock Transactions

Sentiment:

SEC Form 4

📋All filings for Agios Pharmaceuticals, INC
🔒Login to Follow

Director Jacqualyn Fouse of Agios Pharmaceuticals reports acquisition of shares through restricted stock unit vesting and subsequent sale to cover tax obligations.

Summary

  • On April 8, 2024, Jacqualyn Fouse, a director of Agios Pharmaceuticals, acquired 15,934 shares of common stock through the vesting of restricted stock units.
  • On April 10, 2024, Fouse sold 7,791 shares of common stock at a price of $27.55 per share to cover tax withholding obligations related to the vesting of performance share units.
  • Following these transactions, Fouse directly owns 137,396 shares of Agios Pharmaceuticals common stock and 15,933 restricted stock units.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it reflects routine stock transactions by a company director.

Industry Context

This Form 4 filing is a routine disclosure of stock transactions by a company insider, which is a common occurrence in the pharmaceutical industry and provides transparency to investors.

Stakeholder Impact

  • The transactions have a minimal impact on stakeholders as they are related to insider stock activity for tax purposes.

Key Dates

DateDescription
April 8, 2022Date of the reporting person's restricted stock unit agreement.
April 8, 2023Beginning date for the vesting of restricted stock units in three equal annual installments.
April 8, 2024Acquisition of 15,934 shares of common stock through vesting of restricted stock units.
April 10, 2024Sale of 7,791 shares of common stock at $27.55 per share.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.